Asian Paints
2169 -56.80
Cipla
1192.4 -3.50
Eicher Motors
6649.5 -176.00
Nestle India
1191.3 10.50
Grasim Inds
2564.1 -28.70
Hindalco Inds.
916.25 11.65
Hind. Unilever
2065.3 0.60
ITC
292.85 1.15
Trent
3550.6 24.10
Larsen & Toubro
3613.1 5.60
M & M
3011.7 -19.80
Reliance Industries
1350.5 -18.70
Tata Consumer
1042 18.20
Tata Motors PVeh
303.3 0.35
Tata Steel
194.14 -0.46
Wipro
194.91 3.73
Apollo Hospitals
7317.5 12.00
Dr Reddy's Labs
1217.3 7.70
Titan Company
4097.2 31.70
SBI
1018.4 0.60
Shriram Finance
891.6 -8.95
Bharat Electron
421.6 2.90
Kotak Mah. Bank
358 1.95
Infosys
1300.8 25.10
Bajaj Finance
826.85 9.55
Adani Enterp.
1834.2 -8.30
Sun Pharma.Inds.
1693.6 -34.90
JSW Steel
1141.3 0.90
HDFC Bank
750.9 8.65
TCS
2450.7 42.50
ICICI Bank
1215.8 3.10
Power Grid Corpn
289.95 -2.85
Maruti Suzuki
12631 122.00
Axis Bank
1197.9 4.80
HCL Technologies
1402.2 47.80
O N G C
287.2 -0.85
NTPC
359.65 -5.00
Coal India
449.35 -0.05
Bharti Airtel
1789.7 7.80
Tech Mahindra
1441.5 37.00
Jio Financial
229.48 -2.45
Adani Ports
1377.6 -7.80
HDFC Life Insur.
566.1 -6.85
SBI Life Insuran
1774 -16.50
Max Healthcare
944.6 -14.30
UltraTech Cem.
10620 -94.00
Bajaj Auto
8758.5 -137.00
Bajaj Finserv
1640.7 -6.30
Interglobe Aviat
4193.5 12.70
Eternal
231.72 -4.80
Lupin announced the completion of its acquisition of VISUfarma B.V. (VISUfarma), a leading European specialty pharmaceutical company focused on ophthalmology, from GHO Capital Partners LLP (GHO). The acquisition represents a significant milestone in Lupin's strategy to expand its specialty care portfolio and strengthen its presence in Europe.
The integration of VISUfarma has significantly expanded Lupin's ophthalmology portfolio to over 60 branded products spanning dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialty nutraceuticals. VISUfarma's strong commercial footprint across key European markets, including Italy, the UK, Spain, Germany, and France, is strengthened by a highly experienced team with deep ophthalmology expertise, trusted relationships, and strong local market insight.
VISUfarma enhances Lupin's ability to address the growing global demand for innovative eye care solutions, driven by an ageing population and the growing burden of diabetes-related eye complications.